676495
VEGF Inhibitor, V1
The VEGF Inhibitor, V1 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Synonym(s):
VEGF Inhibitor, V1, ATWLPPR
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C40H61N11O9
Molecular Weight:
839.98
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
assay
≥95% (HPLC)
form
lyophilized solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
color
white
solubility
DMSO: 5 mg/mL
shipped in
ambient
storage temp.
2-8°C
General description
An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays (IC50 = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF165 binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC50 = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Specifically competes against VEGF165 binding to recombinant NRP-1
Specifically competes against VEGF165 binding to recombinant NRP-1
Product does not compete with ATP.
Reversible: no
Target IC50: 60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Sequence
H-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH
Other Notes
Starzec, A., et al. 2006. Life Sci.79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J.19, 1525.
Binetruy-Tournaire, R., et al. 2000. EMBO J.19, 1525.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service